– USA, NJ – Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical company developing and commercializing products to treat rare diseases today announced the appointment of Dr. Tim Coté (M.D., M.P.H.) to its Board of Directors.
“We are pleased to welcome Dr. Coté to the Soligenix Board. As Soligenix works with the FDA to advance its rare disease pipeline, including HyBryte (synthetic hypericin sodium) for the treatment of early-stage cutaneous T-cell lymphoma, rare cancer, where it successfully demonstrated statistically significant results in a Phase clinical trial, we aim to leverage Dr. Coté’s extensive regulatory and orphan drug development expertise. We believe his knowledge will add significantly to our already experienced Board of Directors and management team,” said CEO, Dr. Chris Schaber
About Dr. Timothy R. Coté
Dr. Coté is a leading national regulatory expert in orphan drug development. With 23 years of Federal service at the U.S. Food and Drug Administration, National Institutes of Health, and the Centers for Disease Control, Dr. Coté served as the Director of the FDA Office of Orphan Products Development from September 2007 to May 2011. In this role, he implemented the U.S. Orphan Drug Act and personally signed decisions on more than 1,400 orphan drug designation applications. After leaving FDA, Dr. Coté founded Cote Orphan (with a consultancy of 450 clients), where he served as CEO until its sale in 2017 to IQVIA for $20 million. He is currently CEO of Only Orphans Cote LLC, regulatory affairs consulting firm leveraging his expertise and commitment to delivering drugs for rare diseases. He also serves as the CEO of Silk Road Therapeutics, a privately held rare disease company from which Soligenix recently acquired an exclusive option to purchase a novel topical formulation of Pentoxifylline, a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in patient’s suffering from Behçet’s Disease.
“I am eager to join the Soligenix Board of Directors at such an important time for the Company,” said Dr. Coté. “Having spent over 20 years at the FDA, NIH, and CDC, I am confident that my experience will assist Soligenix in navigating the path forward for HyBryte™ and their other rare disease programs. I look forward to collaborating with the Board and management team to further this diverse pipeline.”
Dr. Coté received his bachelor’s degree from Syracuse University, a medical doctorate from the Howard University College of Medicine, and a master’s degree in Public Health from Harvard School of Public Health. An anatomic pathologist and medical epidemiologist, he has published 80 peer-reviewed articles on areas as diverse as HIV/AIDS-related malignancies, typhoid fever epidemics, and the impact of bicycle helmet laws on injury statistics.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward the potential commercialization of HyBryte (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light to treat cutaneous T-cell lymphoma (CTCL).
Source: https://www.soligenix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.